Strategic milestone: Norgine finalizes acquisition of rare disease specialist Theravia

European pharmaceutical company Norgine today announced the successful completion of the acquisition of Theravia, an international specialist in rare and debilitating conditions. This transaction represents a significant step in Norgine’s mission to provide life-changing therapies to patients with high unmet medical needs.

With the acquisition now closed, Norgine will initiate a structured integration process to align systems, operations, and teams.

“We are delighted about the successful closing of this acquisition. By welcoming Theravia, we strengthen our expertise and expand our growing portfolio in rare diseases,” said Janneke van der Kamp, CEO of Norgine. “This is a critical milestone in our growth strategy. With our strong focus on Europe and Australia & New Zealand, we are well positioned to broaden the reach of Theravia’s medicines and deliver them to more patients.”

As a result of the acquisition, Theravia has become a wholly owned subsidiary of Norgin

Norgine is a specialty pharmaceutical and consumer healthcare company with annual revenues of over €550 million and more than 120 years of experience. With strong commercial capabilities, in-house manufacturing, robust supply networks, and deep expertise in regulatory and clinical development, Norgine provides transformative medicines to over 25 million patients annually across Europe, Australia, and New Zealand.

Driven by operational excellence and innovation, Norgine continues to expand the boundaries of therapeutic possibilities while upholding its long-standing legacy of patient-centered care.